Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THIO Sequenced with Libtayo in Advanced Non-Small Cell Lung Cancer
2021-005136-34Phase 2Active
- Sponsor
- MAIA Biotechnology, Inc.
- Start
- Jul 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ateganosine and cemiplimab in non-small cell lung cancer (NSCLC), sponsored by MAIA Biotechnology, Inc. Primary endpoint: Safety and tolerability (DLTs, TEAEs, SAEs). Started Jul 2022; status: active.
02
Drugs
ateganosinecemiplimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2021-005136-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005136-34.